Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Retinoblastoma 22Unspecified Adult Solid Tumor, Protocol Specific 5Sarcoma 4Medulloblastoma 4Central Nervous System Neoplasms 4Rhabdoid Tumor 3Retinal Neoplasms 3Optic Nerve Glioma 3Neuroblastoma 3Carcinoma, Renal Cell 3Astrocytoma 3Wilms Tumor 2Relapsed Pediatric Solid Tumor 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplasms 2Melanoma 2Hepatoblastoma 2Familial ependymoma 2Extensive Stage Small Cell Lung Cancer 2Choroid Plexus Neoplasms 2Advanced Solid Tumors 2Uveal Melanoma 1Urologic Neoplasms 1Unspecified Childhood Solid Tumor, Protocol Specific 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Thyroid Neoplasms 1Thrombocytopenia 1Testicular Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1

Interventions

tislelizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1olaparib 1asciminib 1Topotecan 1Sirolimus 1SAR125844 1Injections 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Solid Tumors × Etoposide × Other solid neoplasm × Clear all
NCT07268040 2026-01-12

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 2 Recruiting
400 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡